Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Anita FloritNuclear Medicine Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli, 8, 00168, Rome, Italy.ORCID 0000-0003-0469-6335
Wyanne A NoortmanDepartment of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0003-0450-951X
Nicolò BizzarriGynaecologic Oncology Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID 0000-0002-1727-904X
Tina PasciutoResearch Core Facility Data Collection G-STeP, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID 0000-0003-2959-8571
Vanessa FeudoSection of Nuclear Medicine, University Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, Italy.ORCID 0000-0001-9753-9472
Salvatore AnnunziataNuclear Medicine Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli, 8, 00168, Rome, Italy.ORCID 0000-0003-3241-1501
Lioe-Fee de Geus-OeiBiomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands.ORCID 0000-0003-1817-2743
Elisabeth PfaehlerInstitute of Neuroscience and Medicine, INM-4, Forschungszentrum Jülich GmbH, Jülich, Germany.ORCID 0000-0002-6160-3011
Ronald BoellaardDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Location VU University Medical Center, Amsterdam, The Netherlands.ORCID 0000-0002-0313-5686
Maria Antonietta GambacortaRadiation Oncology Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID 0000-0001-5455-8737
Gian Franco ZannoniGynaecopathology Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID 0000-0002-4473-7560
Gabriella FerrandinaGynaecologic Oncology Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID 0000-0003-4672-4197
Evis SalaSection of Radiology, University Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, Italy.ORCID 0000-0002-5518-9360
Giovanni ScambiaGynaecologic Oncology Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Vittoria RufiniNuclear Medicine Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli, 8, 00168, Rome, Italy. vittoria.rufini@unicatt.it.ORCID 0000-0002-1045-0633
Floris H P van VeldenSection of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-2859-2119
Angela CollarinoNuclear Medicine Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli, 8, 00168, Rome, Italy.ORCID 0000-0001-6162-9767
Funding
Università Cattolica del Sacro Cuore 2024-R4124501519
6 · The paper itself
Abstract
purposeThis study investigated whether radiomic features extracted from [
methodsWe retrospectively included LACC patients referred to our Institution from 2010 to 2016. [
results95 patients were included. With a median follow-up of 76.0 months (95% CI: 59.5-82.1), 31.6% of patients had recurrence/progression and 20.0% died of disease. None of the models could predict DFS (C-indices ≤ 0.72). Model performances for OS yielded slightly better results, with mean C-indices of 0.75 for both the radiomic and combined model based on early features, 0.79 and 0.78 for the radiomic and combined model derived from delta features, and 0.76 for the clinical models.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
An exploratory assessment of early and delta PET radiomic features for outcome prediction in locally advanced cervical cancer. · full record | OpenQuestion